Introduction {#s1}
============

Myelodysplastic syndrome (MDS), which is characterized by variable degrees of leukopenia and anemia, is one of the most common bone marrow failure syndromes and displays a heterogeneous clinical course including transformation to acute leukemia \[[@R01]\]. Presence of cytogenetic anomalies has a substantial role in determining the prognosis of MDS \[[@R02], [@R03]\]. Among them, isolated 5q deletion (del(5q)) leads to the occurrence of relatively benign form of the disease called 5q-syndrome, which is not usually accompanied with a blast increase in the bone marrow and manifests itself with typical dismegakaryopoiesis, thrombocytosis and severe anemia \[[@R04]\]. In this paper, we present an MDS patient with del(5q) and refractory anemia with excess blasts (10%) (RAEB-1) who was treated successfully with the combination of decitabine and lenalidomide treatment. This is the first case of decitabine plus lenalidomide treatment for an MDS patient with del(5q) and elevated number of blasts.

Case Report {#s2}
===========

A 55-year-old woman with weakness, fatigue and anemia requiring transfusion monthly was referred to our hematology department for further investigation. Her hematologic parameters were as follows: white blood cell (WBC) count of 4,940/mm^3^, neutrophil count of 890/mm^3^, hemoglobin (Hb) level of 8.1 g/dL, mean corpuscular volume (MCV) of 116 fL, and platelet count of 343,000/mm^3^. Because her nutritional and hemolysis parameters were normal, bone marrow biopsy was performed with the provisional diagnosis of MDS. Her bone marrow aspiration showed elevated blast ratio of 10% with dismegakaryopoietic signs. Bone marrow biopsy revealed increase in the number of megakaryocytes, signs of dismegakaryopoiesis. Upon conventional cytogenetical studies she was diagnosed with 5q-syndrome. Decitabine was started at a daily dose of 20 mg/m^2^ 1 - 5 days and lenalidomide was started at daily doses of 10 mg 6 - 20 days in a month. After two cycles, her hemoglobin value increased and transfusion dependency ceased. After four cycles, her hematologic parameters were as follows: WBC of 5,860/mm^3^, neutrophil count of 1,430/mm^3^, Hb level of 10.5 g/dL and platelet count of 201,000/mm^3^. Bone marrow aspiration showed blast ratio of \< 5%. Decitabine and lenalidomide were applied for three more cycles. Hemogram values after seven cycles were as follows: WBC count of 7,150/mm^3^, neutrophil count of 2,780/mm^3^, Hb level of 12.1 g/dL and platelet count of 168,000/mm^3^. Decitabine was terminated after seven cycles and lenalidomide has been continued for 12 months. Most recent blood values (February 2020) were as follows: WBC of 8,670/mm^3^, neutrophil count of 3,470/mm^3^, Hb level of 11.7 g/dL and platelet count of 203,000/mm^3^, and the patient continues to follow-up without treatment ([Figs. 1](#F1){ref-type="fig"}-[](#F2){ref-type="fig"}[](#F3){ref-type="fig"}[4](#F4){ref-type="fig"}).

![Hemoglobin levels: 3 months before treatment, during decitabine plus lenalidomide, 3 years follow-up.](jh-09-033-g001){#F1}

![WBC levels: 3 months before treatment, during decitabine plus lenalidomide, 3 years follow-up. WBC: white blood cell.](jh-09-033-g002){#F2}

![Neutrophil levels: 3 months before treatment, during decitabine plus lenalidomide, 3 years follow-up.](jh-09-033-g003){#F3}

![Platelet levels: 3 months before treatment, during decitabine plus lenalidomide, 3 years follow-up.](jh-09-033-g004){#F4}

Discussion {#s3}
==========

Decitabine is a hypomethylating agent that reactivates tumor suppressor genes by demethylating them. In recent years, decitabine treatment has emerged as a promising therapy in patients with MDS-RAEB and response is usually obtained after 2 - 4 cycles in most of the cases \[[@R05], [@R06]\]. Although decitabine has been mostly used as a monotherapy, several studies showed that combination of decitabine with various agents such as vorinostat, thalidomide and gemtuzumab improved the outcomes in MDS patients \[[@R07]-[@R9]\].

Another treatment of choice in MDS patients is lenalidomide, an immunomodulatory drug that has additional benefits in the regulation of erythropoiesis and reorganization of erythroid production in patients with MDS \[[@R10]\]. Within the subtypes of MDS, lenalidomide has been initially used in isolated 5q-syndrome, a rare form of MDS presenting itself particularly with anemia that requires frequent transfusions. In clinical studies, it has been shown that lenalidomide therapy decreased transfusion dependency prominently in this group of patients \[[@R11], [@R12]\].

The novel data related to the simultaneous administration of lenalidomide and azacytidinin in MDS patients with del(5q) and excess blasts has begun to rise recently \[[@R13]-[@R15]\]. On the other hand, there is inadequate data about the combination of lenalidomide with decitabine, another hypomethylating agent, in those patients. This is the first case of decitabine plus lenalidomide treatment for MDS patient with del(5q) and elevated number of blasts. Although thrombocytopenia and leukopenia have been often observed with the use of either lenalidomide or decitabine \[[@R16], [@R17]\], we did not encounter grade 3/4 neutropenia and thrombocytopenia or any other considerable non-hematological side effects.

In conclusion, combination of lenalidomide and decitabine seems to be an effective treatment modality without a notable side effect in MDS patients with del(5q) and excess blasts. The efficacy of this combination should be validated with studies including large patient groups and with longer follow-up periods.

The case report was accepted for a poster during the 14th International Symposium on Myelodysplastic Syndromes (MDS 2017).
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